Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays
- 19 October 2020
- journal article
- research article
- Published by Elsevier BV in Laboratory Investigation
- Vol. 34 (3), 603-612
- https://doi.org/10.1038/s41379-020-00695-5
Abstract
No abstract availableThis publication has 62 references indexed in Scilit:
- Integrated genomic characterization of endometrial carcinomaNature, 2013
- Does Breast Tumor Heterogeneity Necessitate Further Immunohistochemical Staining on Surgical Specimens?Journal of the American College of Surgeons, 2013
- Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinomaCancer Science, 2012
- Targeted therapies for breast cancerJCI Insight, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group studyGynecologic Oncology, 2010
- An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: A gynecologic oncology group studyGynecologic Oncology, 2008
- The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesisOncogene, 2007
- Her-2/neu Overexpression and Amplification in Uterine Papillary Serous CarcinomaJournal of Clinical Oncology, 2004
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987